Research Article
The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid
Table 1
Subject characteristics.
| Characteristic° | Crohn’s disease ( = 10) | Ulcerative colitis ( = 10) | Healthy volunteers ( = 15) |
| Age (years) mean ± SD | 39 ± 11 | 34 ± 10 | 28 ± 8 | Male (%) | 6 (60) | 4 (40) | 5 (33.3) | Current smoker (%) | 3 (30) | 1 (10) | 4 (26.6) | Duration of disease (months) | | | | Mean ± SD | 68 ± 32 | 65 ± 28 | — | Previous intestinal resection (%) | 2 (20) | 0 (0) | 0 (0) | CDAI* | | | | Median (range) | 82 (38–102) | / | / | SCCAI* | | | | Median (range) | / | 0 (0) | / | Site of involvement (%) | | | | Ileum | 4 (40) | / | / | Ileum and colon | 3 (30) | / | / | Colon | 3 (30) | / | / | Pancolitis | / | 3 (30) | / | Left-sided colitis | / | 7 (70) | / | Ongoing drug therapy (%) | | | | Immunosuppressive agents | 4 (40) | 2 (20) | / | Mesalamine | 6 (60) | 8 (80) | |
|
|
CDAI: Crohn’s disease activity index; SCCAI: simple clinical colitis activity index; = ns.
|